TY - JOUR
T1 - PML during dimethyl fumarate treatment of multiple sclerosis
T2 - How does lymphopenia matter?
AU - Lehmann-Horn, Klaus
AU - Penkert, Horst
AU - Grein, Peter
AU - Leppmeier, Ulrich
AU - Teuber-Hanselmann, Sarah
AU - Hemmer, Bernhard
AU - Berthele, Achim
N1 - Publisher Copyright:
© 2016 American Academy of Neurology.
PY - 2016/7/26
Y1 - 2016/7/26
N2 - Progressive multifocal leukoencephalopathy (PML), which is caused by the John Cunningham virus (JCV), is a rare brain disease that results in persistent neurologic disability or death. In multiple sclerosis (MS), PML is a major concern in patients treated with natalizumab, and treatment duration (more than 2 years), preceding immunosuppression, and JCV antibody serostatus are identified risk factors, which are used for risk stratification, patient monitoring, and counseling.
AB - Progressive multifocal leukoencephalopathy (PML), which is caused by the John Cunningham virus (JCV), is a rare brain disease that results in persistent neurologic disability or death. In multiple sclerosis (MS), PML is a major concern in patients treated with natalizumab, and treatment duration (more than 2 years), preceding immunosuppression, and JCV antibody serostatus are identified risk factors, which are used for risk stratification, patient monitoring, and counseling.
UR - http://www.scopus.com/inward/record.url?scp=84980327274&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000002900
DO - 10.1212/WNL.0000000000002900
M3 - Short survey
C2 - 27343070
AN - SCOPUS:84980327274
SN - 0028-3878
VL - 87
SP - 440
EP - 441
JO - Neurology
JF - Neurology
IS - 4
ER -